453 related articles for article (PubMed ID: 25033833)
1. Influence of secreted frizzled receptor protein 1 (SFRP1) on neoadjuvant chemotherapy in triple negative breast cancer does not rely on WNT signaling.
Bernemann C; Hülsewig C; Ruckert C; Schäfer S; Blümel L; Hempel G; Götte M; Greve B; Barth PJ; Kiesel L; Liedtke C
Mol Cancer; 2014 Jul; 13():174. PubMed ID: 25033833
[TBL] [Abstract][Full Text] [Related]
2. Correlation between SFRP1 expression and clinicopathological parameters in patients with triple-negative breast cancer.
Schäfer SA; Hülsewig C; Barth P; von Wahlde MK; Tio J; Kolberg HC; Bernemann C; Blohmer JU; Kiesel L; Kolberg-Liedtke C
Future Oncol; 2019 Jun; 15(16):1921-1938. PubMed ID: 31140870
[No Abstract] [Full Text] [Related]
3. Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection.
Lehmann BD; Jovanović B; Chen X; Estrada MV; Johnson KN; Shyr Y; Moses HL; Sanders ME; Pietenpol JA
PLoS One; 2016; 11(6):e0157368. PubMed ID: 27310713
[TBL] [Abstract][Full Text] [Related]
4. Gene signature-based prediction of triple-negative breast cancer patient response to Neoadjuvant chemotherapy.
Zhao Y; Schaafsma E; Cheng C
Cancer Med; 2020 Sep; 9(17):6281-6295. PubMed ID: 32692484
[TBL] [Abstract][Full Text] [Related]
5. Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy.
Darb-Esfahani S; Denkert C; Stenzinger A; Salat C; Sinn B; Schem C; Endris V; Klare P; Schmitt W; Blohmer JU; Weichert W; Möbs M; Tesch H; Kümmel S; Sinn P; Jackisch C; Dietel M; Reimer T; Loi S; Untch M; von Minckwitz G; Nekljudova V; Loibl S
Oncotarget; 2016 Oct; 7(42):67686-67698. PubMed ID: 27611952
[TBL] [Abstract][Full Text] [Related]
6. WNT signaling enhances breast cancer cell motility and blockade of the WNT pathway by sFRP1 suppresses MDA-MB-231 xenograft growth.
Matsuda Y; Schlange T; Oakeley EJ; Boulay A; Hynes NE
Breast Cancer Res; 2009; 11(3):R32. PubMed ID: 19473496
[TBL] [Abstract][Full Text] [Related]
7. In vivo and in vitro effects of microRNA-27a on proliferation, migration and invasion of breast cancer cells through targeting of SFRP1 gene via Wnt/β-catenin signaling pathway.
Kong LY; Xue M; Zhang QC; Su CF
Oncotarget; 2017 Feb; 8(9):15507-15519. PubMed ID: 28099945
[TBL] [Abstract][Full Text] [Related]
8. BDNF is associated with SFRP1 expression in luminal and basal-like breast cancer cell lines and primary breast cancer tissues: a novel role in tumor suppression?
Huth L; Rose M; Kloubert V; Winkens W; Schlensog M; Hartmann A; Knüchel R; Dahl E
PLoS One; 2014; 9(7):e102558. PubMed ID: 25036590
[TBL] [Abstract][Full Text] [Related]
9. Altered glycometabolism affects both clinical features and prognosis of triple-negative and neoadjuvant chemotherapy-treated breast cancer.
Dong T; Kang X; Liu Z; Zhao S; Ma W; Xuan Q; Liu H; Wang Z; Zhang Q
Tumour Biol; 2016 Jun; 37(6):8159-68. PubMed ID: 26715276
[TBL] [Abstract][Full Text] [Related]
10. The anti-androgen drug dutasteride renders triple negative breast cancer cells more sensitive to chemotherapy via inhibition of HIF-1α-/VEGF-signaling.
von Wahlde MK; Hülsewig C; Ruckert C; Götte M; Kiesel L; Bernemann C
Gynecol Endocrinol; 2015 Feb; 31(2):160-4. PubMed ID: 25356777
[TBL] [Abstract][Full Text] [Related]
11. Functional analyses and prognostic significance of SFRP1 expression in bladder cancer.
Rogler A; Kendziorra E; Giedl J; Stoehr C; Taubert H; Goebell PJ; Wullich B; Stöckle M; Lehmann J; Petsch S; Hartmann A; Stoehr R
J Cancer Res Clin Oncol; 2015 Oct; 141(10):1779-90. PubMed ID: 25732201
[TBL] [Abstract][Full Text] [Related]
12. Wnt signaling blockage inhibits cell proliferation and migration, and induces apoptosis in triple-negative breast cancer cells.
Bilir B; Kucuk O; Moreno CS
J Transl Med; 2013 Nov; 11():280. PubMed ID: 24188694
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of beta-catenin in chemo-tolerant TNBC through changes in receptor and antagonist profiles of the WNT pathway: Clinical and prognostic implications.
Islam S; Dasgupta H; Basu M; Roy A; Alam N; Roychoudhury S; Panda CK
Cell Oncol (Dordr); 2020 Aug; 43(4):725-741. PubMed ID: 32430683
[TBL] [Abstract][Full Text] [Related]
14. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
[TBL] [Abstract][Full Text] [Related]
15. GSK3β regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer.
Vijay GV; Zhao N; Den Hollander P; Toneff MJ; Joseph R; Pietila M; Taube JH; Sarkar TR; Ramirez-Pena E; Werden SJ; Shariati M; Gao R; Sobieski M; Stephan CC; Sphyris N; Miura N; Davies P; Chang JT; Soundararajan R; Rosen JM; Mani SA
Breast Cancer Res; 2019 Mar; 21(1):37. PubMed ID: 30845991
[TBL] [Abstract][Full Text] [Related]
16. Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.
Telli ML; Hellyer J; Audeh W; Jensen KC; Bose S; Timms KM; Gutin A; Abkevich V; Peterson RN; Neff C; Hughes E; Sangale Z; Jones J; Hartman AR; Chang PJ; Vinayak S; Wenstrup R; Ford JM
Breast Cancer Res Treat; 2018 Apr; 168(3):625-630. PubMed ID: 29275435
[TBL] [Abstract][Full Text] [Related]
17. Methylation-associated silencing of SFRP1 with an 8p11-12 amplification inhibits canonical and non-canonical WNT pathways in breast cancers.
Yang ZQ; Liu G; Bollig-Fischer A; Haddad R; Tarca AL; Ethier SP
Int J Cancer; 2009 Oct; 125(7):1613-21. PubMed ID: 19569235
[TBL] [Abstract][Full Text] [Related]
18. Estrogen-mediated signaling is differentially affected by the expression levels of Sfrp1 in mammary epithelial cells.
Gregory KJ; Schneider SS
Cell Biol Int; 2015 Jul; 39(7):873-9. PubMed ID: 25809273
[TBL] [Abstract][Full Text] [Related]
19. Low Dose of Paclitaxel Combined with XAV939 Attenuates Metastasis, Angiogenesis and Growth in Breast Cancer by Suppressing Wnt Signaling.
Shetti D; Zhang B; Fan C; Mo C; Lee BH; Wei K
Cells; 2019 Aug; 8(8):. PubMed ID: 31416135
[TBL] [Abstract][Full Text] [Related]
20. Response of Triple Negative Breast Cancer to Neoadjuvant Chemotherapy: Correlation between Ki-67 Expression and Pathological Response.
Elnemr GM; El-Rashidy AH; Osman AH; Issa LF; Abbas OA; Al-Zahrani AS; El-Seman SM; Mohammed AA; Hassan AA
Asian Pac J Cancer Prev; 2016; 17(2):807-13. PubMed ID: 26925684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
